% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Aboagye:186695,
      author       = {E. O. Aboagye and T. D. Barwick and U. Haberkorn$^*$},
      title        = {{R}adiotheranostics in oncology: {M}aking precision
                      medicine possible.},
      journal      = {CA},
      volume       = {73},
      number       = {3},
      issn         = {0007-9235},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2023-00064},
      pages        = {255-274},
      year         = {2023},
      note         = {#LA:E060# / 2023 May-Jun;73(3):255-274},
      abstract     = {A quintessential setting for precision medicine,
                      theranostics refers to a rapidly evolving field of medicine
                      in which disease is diagnosed followed by treatment of
                      disease-positive patients using tools for the therapy
                      identical or similar to those used for the diagnosis.
                      Against the backdrop of only-treat-when-visualized, the goal
                      is a high therapeutic index with efficacy markedly
                      surpassing toxicity. Oncology leads the way in theranostics
                      innovation, where the approach has become possible with the
                      identification of unique proteins and other factors
                      selectively expressed in cancer versus healthy tissue,
                      advances in imaging technology able to report these tissue
                      factors, and major understanding of targeting chemicals and
                      nanodevices together with methods to attach labels or
                      warheads for imaging and therapy. Radiotheranostics-using
                      radiopharmaceuticals-is becoming routine in patients with
                      prostate cancer and neuroendocrine tumors who express the
                      proteins PSMA (prostate-specific membrane antigen) and SSTR2
                      (somatostatin receptor 2), respectively, on their cancer.
                      The palpable excitement in the field stems from the finding
                      that a proportion of patients with large metastatic burden
                      show complete and partial responses, and this outcome is
                      catalyzing the search for more radiotheranostics approaches.
                      Not every patient will benefit from radiotheranostics; but,
                      for those who cross the target-detected line, the likelihood
                      of response is very high.},
      subtyp        = {Review Article},
      keywords     = {metastatic cancer (Other) / molecularly targeted therapies
                      (Other) / nuclear medicine (Other) / pharmacology (Other) /
                      positron emission tomography (Other) / radioisotopes (Other)
                      / radiotheranostics (Other) / theranostics audit trail
                      (Other)},
      cin          = {E060},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36622841},
      doi          = {10.3322/caac.21768},
      url          = {https://inrepo02.dkfz.de/record/186695},
}